Pliant Therapeutics Reports Promising Early Data for PLN-101095 in Cancer Trial

Pliant Therapeutics has unveiled promising interim results from its ongoing Phase 1 clinical trial evaluating PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, in combination with pembrolizumab for patients with ICI-refractory advanced or metastatic solid tumors. Among the first three cohorts, three partial responses were observed in patients receiving the 1000 mg twice-daily dose, leading to an objective response rate of 50% at the highest tested dose. The treatment was well tolerated across all dose levels, indicating a potential new approach to overcoming resistance in immunotherapy.

The trial enrolled nine patients across six different tumor types, who initially received PLN-101095 alone for 14 days at escalating doses of 250 mg, 500 mg, or 1000 mg, followed by combination treatment with pembrolizumab. Patients underwent regular scans to assess tumor response, with encouraging signs of anti-tumor activity emerging in the higher dose cohort. As the study progresses, additional data from the remaining cohorts will help further define PLN-101095’s role in enhancing checkpoint inhibitor therapy for difficult-to-treat cancers.